Our perspectives
in one place
Topic
Selected filters
Clear
News
See allStatement on PABS Instrument at the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement
On 6 July 2026, IFPMA published a statement ahead of the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement.
Read more
WIPO, IFPMA and Interpat join forces to support health innovation through IP management clinics
Read moreGlobal biopharmaceutical CEOs response to reforms introduced in Germany
On 30 June, in response to reforms introduced in Germany, BCR Secretary General, and IFPMA Director General, Dr. David Reddy, said: “The legislation introduced by the German government undermines the value of medical innovation, global competitiveness and patient access to new medicines. Pricing and reimbursement policies which fail to reflect the value that medicines and...
Read more2026 UN High-Level Meeting on HIV/AIDS
On 22 June 2026, IFPMA delivered a statement at the UN High-Level Meeting on HIV/AIDS in New York. Excellencies, distinguished delegates, I am pleased to speak on behalf of the IFPMA, representing the innovative pharmaceutical industry. As Member States gather at this High-Level Meeting to renew global commitments on HIV/AIDS, IFPMA welcomes the Political Declaration’s...
Read morePharmaceutical innovation key to delivering G7 leaders’ growth agenda
The global innovative pharmaceutical industry welcomes the G7 leaders’ commitment to strengthening international cooperation and advancing a balanced and durable growth agenda. IFPMA reiterates that a strong life sciences sector is critical to support these shared objectives.
Read morePharmaceutical industry mobilizes to support response to the Ebola Bundibugyo virus disease outbreak and calls for a system that enables rapid response and sustained R&D investment
The global pharmaceutical industry underlines the commitment of the sector to support the response to the latest Ebolavirus outbreak, and calls for the latest outbreak to be a “wake up call” for negotiators discussing the details of the Pandemic Agreement.
Read morePublications
See allInternational data flows: Enabling data-driven, patient-centric innovative pharmaceutical research and development (R&D)
To fulfill the potential of data and new technologies in supporting the shared objective of improving patient lives and population health, it is vital that well-designed systems are put in place.
Read more
Enabling innovation: The R&D ecosystem for medicines and vaccines
Decisive policy action is critical to sustain innovation that improves people’s lives. This position paper illustrates the R&D ecosystem in action, and underscores the importance of continued commitment by governments and across stakeholders to ensure the conditions that enable the development and delivery of transformative medicines and vaccines.
Read more
IFPMA Note for Guidance on educational and scientific events (2026 update)
Collaborations between healthcare professionals (HCPs) and the pharmaceutical industry are essential and ensure that patients have access to the medicines they need and that healthcare professionals have up-to-date comprehensive information about the diseases they treat and the medicines they prescribe.
Read more
Expert insights
See all
Building pandemic readiness through routine vaccination
Read more
The G7 cannot afford to lose its leadership in pharmaceutical innovation
Read more
Innovative medicines as drivers of economic security – A strategic imperative for G7 economies
Read moreResources
See allAdult immunization for healthy workforces and healthy economies in an aging world
IFPMA and the Global Coalition on Ageing (GCOA) outline why vaccination is essential to building healthier workforces and stronger economies in an aging world.
Read more
Streamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more
Our Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more